Literature DB >> 16298202

Fabry's disease--an important risk factor for stroke.

Raphael Schiffmann1, Markus Ries.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16298202     DOI： 10.1016/S0140-6736(05)67636-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.

Authors:  Sang H Shin; Stefanie Kluepfel-Stahl; Adele M Cooney; Christine R Kaneski; Jane M Quirk; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  Pharmacogenet Genomics       Date:  2008-09       Impact factor: 2.089

2.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

3.  Cellular and tissue distribution of intravenously administered agalsidase alfa.

Authors:  Gary J Murray; Miriam R Anver; Maureen A Kennedy; Jane M Quirk; Raphael Schiffmann
Journal:  Mol Genet Metab       Date:  2006-12-22       Impact factor: 4.797

4.  Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

Authors:  Raphael Schiffmann; Hasan Askari; Margaret Timmons; Chevalia Robinson; William Benko; Roscoe O Brady; Markus Ries
Journal:  J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 10.121

5.  Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Authors:  C Auray-Blais; D S Millington; S P Young; J T R Clarke; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-01-26       Impact factor: 4.982

6.  Fabry disease and early stroke.

Authors:  U Feldt-Rasmussen
Journal:  Stroke Res Treat       Date:  2011-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.